Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 73

Results For "PLI"

4300 News Found

Sharda Hospital performs Greater Noida’s first kidney transplant Under Ayushman Bharat
Hospitals | April 09, 2026

Sharda Hospital performs Greater Noida’s first kidney transplant Under Ayushman Bharat

Landmark procedure restores 32-year-old CKD patient’s health, highlighting how public insurance is widening access to advanced renal care


Kokilaben hospital performs first remote robotic kidney surgery
Hospitals | April 09, 2026

Kokilaben hospital performs first remote robotic kidney surgery

Surgeon Yuvaraja operates on a 55-year-old patient at Medical City Hospital Muscat


BOTOX Cosmetic launches programme to empower 250 women entrepreneurs
News | April 09, 2026

BOTOX Cosmetic launches programme to empower 250 women entrepreneurs

20 among them to receive $20,000 grants


Dr. Jitendra Singh urges industry to step up R&D collaboration
R&D | April 09, 2026

Dr. Jitendra Singh urges industry to step up R&D collaboration

Minister highlights RDI fund, private participation in space and nuclear sectors, and calls for faster reforms to improve ease of research in India


India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters
Drug Approval | April 09, 2026

India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters

In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga


IndiaAI, CDSCO launch hackathon to accelerate health innovation approvals
Digitisation | April 08, 2026

IndiaAI, CDSCO launch hackathon to accelerate health innovation approvals

AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17


Biocon launches denosumab biosimilars Bosaya and Aukelso in US market
Biopharma | April 08, 2026

Biocon launches denosumab biosimilars Bosaya and Aukelso in US market

Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market


Solara Active Pharma dispatches final rights share call notice; Rs 112.5 per share due by May 7
News | April 08, 2026

Solara Active Pharma dispatches final rights share call notice; Rs 112.5 per share due by May 7

API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle